An efficient T-cell epitope discovery strategy using in silico prediction and the iTopia assay platform
Open Access
- 4 November 2012
- journal article
- Published by Taylor & Francis in OncoImmunology
- Vol. 1 (8) , 1258-1270
Abstract
Functional T-cell epitope discovery is a key process for the development of novel immunotherapies, particularly for cancer immunology. In silico epitope prediction is a common strategy to try to achieve this objective. However, this approach suffers from a significant rate of false-negative results and epitope ranking lists that often are not validated by practical experience. A high-throughput platform for the identification and prioritization of potential T-cell epitopes is the iTopiaTM Epitope Discovery SystemTM, which allows measuring binding and stability of selected peptides to MHC Class I molecules. So far, the value of iTopia combined with in silico epitope prediction has not been investigated systematically. In this study, we have developed a novel in silico selection strategy based on three criteria: (1) predicted binding to one out of five common MHC Class I alleles; (2) uniqueness to the antigen of interest; and (3) increased likelihood of natural processing. We predicted in silico and characterized by iTopia 225 candidate T-cell epitopes and fixed-anchor analogs from three human tumor-associated antigens: CEA, HER2 and TERT. HLA-A2-restricted fragments were further screened for their ability to induce cell-mediated responses in HLA-A2 transgenic mice. The iTopia binding assay was only marginally informative while the stability assay proved to be a valuable experimental screening method complementary to in silico prediction. Thirteen novel T-cell epitopes and analogs were characterized and additional potential epitopes identified, providing the basis for novel anticancer immunotherapies. In conclusion, we show that combination of in silico prediction and an iTopia-based assay may be an accurate and efficient method for MHC Class I epitope discovery among tumor-associated antigens.Keywords
This publication has 61 references indexed in Scilit:
- Anti-HER2 vaccines: new prospects for breast cancer therapyCancer Immunology, Immunotherapy, 2010
- Coadministration of Telomerase Genetic Vaccine and a Novel TLR9 Agonist in Nonhuman PrimatesMolecular Therapy, 2009
- Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigenProceedings of the National Academy of Sciences, 2008
- Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide librariesImmunome Research, 2008
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptidesin vivoand plays an important role in immunodominanceProceedings of the National Academy of Sciences, 2006
- A Community Resource Benchmarking Predictions of Peptide Binding to MHC-I MoleculesPLOS Computational Biology, 2006
- Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vectorInternational Journal of Cancer, 2004
- Reliable prediction of T‐cell epitopes using neural networks with novel sequence representationsProtein Science, 2003
- H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategiesEuropean Journal of Immunology, 1999